The risk of second primary cancer after nasopharyngeal cancer: a systematic review.


Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 05 06 2023
accepted: 18 07 2023
medline: 2 1 2024
pubmed: 27 7 2023
entrez: 26 7 2023
Statut: ppublish

Résumé

Second primary cancers (SPCs) after nasopharyngeal cancer (NPC) are rare, but have an impact on the follow-up of this patient population. The aim of this study is to systematically review the literature to determine the prevalence and most typical sites of SPCs after NPC. We searched the databases of PubMed, Web of Science, and Scopus for articles on SPCs after NPC. The Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines were followed. This review includes data on 89 168 patients with NPC from 21 articles. The mean occurrence for SPCs was 6.6% and varied from 4.9% in endemic areas to 8.7% in non-endemic areas. The most frequent locations of SPCs were oral cavity, pharynx, nose and paranasal sinuses, esophagus and lung. There is an increased risk for a SPC after NPC management, especially in non-endemic areas. However, their mean rate is lower than after other head and neck carcinomas.

Identifiants

pubmed: 37495725
doi: 10.1007/s00405-023-08144-0
pii: 10.1007/s00405-023-08144-0
pmc: PMC10562268
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

4775-4781

Informations de copyright

© 2023. The Author(s).

Références

Chang ET, Ye W, Zeng YX, Adami H-O (2021) The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsor Am Soc Prev Oncol 30(6):1035–1047. https://doi.org/10.1158/1055-9965.EPI-20-1702
doi: 10.1158/1055-9965.EPI-20-1702
Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet Lond Engl 394(10192):64–80. https://doi.org/10.1016/S0140-6736(19)30956-0
doi: 10.1016/S0140-6736(19)30956-0
Coca-Pelaz A, Rodrigo J, Suáres C et al (2020) The risk of second primary tumors in head and neck cancer: a systematic review. Head Neck 42(3):456–466. https://doi.org/10.1002/hed.26016
doi: 10.1002/hed.26016 pubmed: 31750595
Hoxhaj I, Hysaj O, Vucovic V, Leoncini E, Amore R, Pastorino R, Boccia S (2020) Occurrence of metachronous second primary cancer in head and neck cancer survivors: a systematic review and meta-analysis of the literature. Eur J Cancer Care (Engl). https://doi.org/10.1111/ecc.13255
doi: 10.1111/ecc.13255 pubmed: 32400912
van der Waal I, de Bree R (2010) Second primary tumours in oral cancer. Oral Oncol 46(6):426–428. https://doi.org/10.1016/j.oraloncology.2010.02.018
doi: 10.1016/j.oraloncology.2010.02.018 pubmed: 20308001
Gao X, Fisher SG, Mohideen N, Emami B (2003) Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol 56(2):427–435. https://doi.org/10.1016/S0360-3016(02)04613-8
doi: 10.1016/S0360-3016(02)04613-8
Atienza JAS, Dasanu CA (2012) Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature. Curr Med Res Opin 28(12):1899–1909. https://doi.org/10.1185/03007995.2012.746218
doi: 10.1185/03007995.2012.746218 pubmed: 23121148
Ayan I, Altun M (1996) Nasopharyngeal carcinoma in children: retrospective review of 50 patients. Int J Radiat Oncol Biol Phys 35(3):485–492. https://doi.org/10.1016/s0360-3016(96)80010-1
doi: 10.1016/s0360-3016(96)80010-1 pubmed: 8655371
Wang C-C, Chen M-L, Hsu K-H et al (2000) Second malignant tumors in patients with nasopharyngeal carcinoma and their association with Epstein-Barr virus. Int J Cancer 87(2):228–231
doi: 10.1002/1097-0215(20000715)87:2<228::AID-IJC12>3.0.CO;2-T pubmed: 10861479
Cağlar K, Varas A, Akyüz C et al (2006) Second neoplasms in pediatric patients treated for cancer: a center’s 30-year experience. J Pediatr Hematol Oncol 28(6):374–378. https://doi.org/10.1097/00043426-200606000-00010
doi: 10.1097/00043426-200606000-00010 pubmed: 16794506
Kong L, Lu JJ, Hu C, Guo X, Wu Y, Zhang Y (2006) The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy. Cancer 107(6):1287–1293. https://doi.org/10.1002/cncr.22119
doi: 10.1002/cncr.22119 pubmed: 16909425
Scélo G, Boffetta P, Corbex M et al (2007) Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. Cancer Causes Control CCC 18(3):269–278. https://doi.org/10.1007/s10552-006-0101-z
doi: 10.1007/s10552-006-0101-z pubmed: 17237987
Tsou Y-A, Hua C-H, Tseng H-C, Lin M-H, Tsai M-H (2007) Survival study and treatment strategy for second primary malignancies in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Acta Otolaryngol (Stockh.) 127(6):651–657. https://doi.org/10.1080/00016480600951517
doi: 10.1080/00016480600951517 pubmed: 17503236
Chen M-C, Feng I-J, Lu C-H et al (2008) The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979–2003). Ann Oncol Off J Eur Soc Med Oncol 19(6):1180–1186. https://doi.org/10.1093/annonc/mdn003
doi: 10.1093/annonc/mdn003
Sultan I, Casanova M, Ferrari A, Rihani R, Rodriguez-Galindo C (2010) Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer 55(2):279–284. https://doi.org/10.1002/pbc.22521
doi: 10.1002/pbc.22521 pubmed: 20582982
Goggins WB, Yu ITS, Tse LA, Leung SF, Tung SY, Yu KS (2010) Risk of second primary malignancies following nasopharyngeal carcinoma in Hong Kong. Cancer Caus Control CCC 21(9):1461–1466. https://doi.org/10.1007/s10552-010-9574-x
doi: 10.1007/s10552-010-9574-x
Cheuk DKL, Billups CA, Martin MG et al (2011) Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 117(1):197–206. https://doi.org/10.1002/cncr.25376
doi: 10.1002/cncr.25376 pubmed: 20737561
Liao LJ, Chou HW, Wang CT, Chung CS, Lai MS (2013) The impact of second primary malignancies on head and neck cancer survivors: a nationwide cohort study. PLoS ONE 8(4):e62116. https://doi.org/10.1371/journal.pone.0062116
doi: 10.1371/journal.pone.0062116 pubmed: 23614023 pmcid: 3628575
Lin C, Lin S-W, Weng S-F, Lin Y-S (2014) Risk of second primary malignancies after nasopharyngeal carcinoma: a population-based cohort study in Taiwan. Head Neck 36(2):209–214. https://doi.org/10.1002/hed.23281
doi: 10.1002/hed.23281 pubmed: 23729214
Chan JYK, Gooi Z, Mydlarz WK, Agrawal N (2016) Risk of second primary malignancy after nasopharyngeal carcinoma in the United States: a population-based study. Head Neck 38(Suppl 1):E1130-1136. https://doi.org/10.1002/hed.24173
doi: 10.1002/hed.24173 pubmed: 26314805
Ooft ML, van Ipenburg J, Braunius WW et al (2016) A nation-wide epidemiological study on the risk of developing second malignancies in patients with different histological subtypes of nasopharyngeal carcinoma. Oral Oncol 56:40–46. https://doi.org/10.1016/j.oraloncology.2016.02.009
doi: 10.1016/j.oraloncology.2016.02.009 pubmed: 27086485
Zhao W, Lei H, Zhu X et al (2016) The clinical characteristics of secondary primary tumors in patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy: A retrospective analysis. Medicine (Baltimore) 95(45):e5364. https://doi.org/10.1097/MD.0000000000005364
doi: 10.1097/MD.0000000000005364 pubmed: 27828863
Chow JCH, Au KH, Mang OWK, Cheung KM, Ngan RKC (2019) Risk, pattern and survival impact of second primary tumors in patients with nasopharyngeal carcinoma following definitive intensity-modulated radiotherapy. Asia Pac J Clin Oncol 15(1):48–55. https://doi.org/10.1111/ajco.12994
doi: 10.1111/ajco.12994 pubmed: 29932287
Ben-Ami T, Ash S, Ben-Harosh M, Gavriel H, Weintraub M, Revel-Vilk S, Ben-Arush M (2020) Nasopharyngeal carcinoma in children and young adults-beyond 5-year survival. Pediatr Blood Cancer 67(9):e28494. https://doi.org/10.1002/pbc.28494
doi: 10.1002/pbc.28494 pubmed: 32573923
Chow JCH, Tam AHP, Cheung K-M et al (2020) Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: a territory-wide study by HKNPCSG. Oral Oncol 111:105012. https://doi.org/10.1016/j.oraloncology.2020.105012
doi: 10.1016/j.oraloncology.2020.105012 pubmed: 32980659
Bay SB, Ozkaya K, KebudI R, Altun M (2021) Second primary malignancies in pediatric and adolescent nasopharyngeal carcinoma survivors: experience of a single-center. TURK Onkol Derg Turk J Oncol 36(3):267–272. https://doi.org/10.5505/tjo.2021.2805
doi: 10.5505/tjo.2021.2805
Kebud R, Buyukkapu SB, Gorgun O, Ozkaya K, Meral R, Ayan I, Altun M (2021) Nasopharyngeal carcinoma in children: Multimodal treatment and long-term outcome of 92 patients in a single center over a 28-year period. Pediatr Blood Cancer 68(12):e29372. https://doi.org/10.1002/pbc.29372
doi: 10.1002/pbc.29372
Niu X, Xue F, Liu P, Hu C, He X (2022) Long-term outcomes of nasopharyngeal carcinoma patients with T1–2 stage in intensity-modulated radiotherapy era. Int J Med Sci 19(2):267–273. https://doi.org/10.7150/ijms.68394
doi: 10.7150/ijms.68394 pubmed: 35165512 pmcid: 8795811
Xi M, Liu S-L, Zhao L et al (2013) Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma. PLoS ONE 8(12):e84586. https://doi.org/10.1371/journal.pone.0084586
doi: 10.1371/journal.pone.0084586 pubmed: 24367679 pmcid: 3867505
Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5):963–968
doi: 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q pubmed: 13094644
Xu F-H, Xiong D, Xu Y-F et al (2012) An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst 104(18):1396–1410. https://doi.org/10.1093/jnci/djs320
doi: 10.1093/jnci/djs320 pubmed: 22972969
Tham T, Machado R, Russo DP, Herman SW, Teegala S, Costantino P (2021) Viral markers in nasopharyngeal carcinoma: a systematic review and meta-analysis on the detection of p16INK4a, human papillomavirus (HPV), and Ebstein-Barr virus (EBV). Am J Otolaryngol 42(1):102762. https://doi.org/10.1016/j.amjoto.2020.102762
doi: 10.1016/j.amjoto.2020.102762 pubmed: 33202328
King AD, Ahuja AT, Yeung DK et al (2007) Delayed complications of radiotherapy treatment for nasopharyngeal carcinoma: imaging findings. Clin Radiol 62(3):195–203. https://doi.org/10.1016/j.crad.2006.10.011
doi: 10.1016/j.crad.2006.10.011 pubmed: 17293211
Tubiana M (2009) Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol J Eur Soc Ther Radiol Oncol 91(1):4–15. https://doi.org/10.1016/j.radonc.2008.12.016 . (discussion 1–3)
doi: 10.1016/j.radonc.2008.12.016
Williams PO, Hounsell AR (2001) X-ray leakage considerations for IMRT. Br J Radiol 74(877):98–100. https://doi.org/10.1259/bjr.74.877.740098
doi: 10.1259/bjr.74.877.740098 pubmed: 11227786
Hall EJ, Wuu C-S (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56(1):83–88. https://doi.org/10.1016/s0360-3016(03)00073-7
doi: 10.1016/s0360-3016(03)00073-7 pubmed: 12694826
Neugut AI, Robinson E, Meadows AT (1999) Multiple primary cancers. Lippincott Williams & Wilkins, Philadelphia, p 484
Silén S, Haapaniemi A, Dickinson A, Rönn K, Mäkitie A (2019) Presentation of second primary cancers in young laryngeal carcinoma patients. Acta Otolaryngol (Stockh) 139(1):85–89. https://doi.org/10.1080/00016489.2018.1527037
doi: 10.1080/00016489.2018.1527037 pubmed: 30712430
Warren S (1932) Multiple primary malignant tumors. A survey of the literature and a statistical study. Am J Cancer 16:1359–1414
King AD, Ahuja AT, Teo P, Tse GM, Kew J (2000) Radiation induced sarcomas of the head and neck following radiotherapy for nasopharyngeal carcinoma. Clin Radiol 55(9):684–689. https://doi.org/10.1053/crad.2000.0503
doi: 10.1053/crad.2000.0503 pubmed: 10988046
Wang X, Li Y, Gao Y, Ouyang D, Guo Z (2018) Second primary squamous cell carcinoma in patients with nasopharyngeal carcinoma after radiotherapy—predictors and prognostic factors. Head Neck 40(7):1434–1442. https://doi.org/10.1002/hed.25130
doi: 10.1002/hed.25130 pubmed: 29522261

Auteurs

Fanni Svärd (F)

Department of Otorhinolaryngology, Kuopio University Hospital, Kuopio, Finland.

Rasheed Omobolaji Alabi (RO)

Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Ilmo Leivo (I)

Institute of Biomedicine, Pathology, University of Turku, Turku, Finland.

Antti A Mäkitie (AA)

Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. antti.makitie@helsinki.fi.
Department of Otorhinolaryngology, Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. antti.makitie@helsinki.fi.
Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. antti.makitie@helsinki.fi.

Alhadi Almangush (A)

Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Department of Pathology, University of Helsinki, P.O. Box 21, 00014, Helsinki, Finland.
Institute of Biomedicine, Pathology, University of Turku, Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH